BAYRY Gross Margin Analysis

BAYRY’s gross margin of 61.0% means that for every dollar of revenue, the company keeps 61 cents after covering the direct costs of producing its goods (e.g., raw materials and manufacturing), with the remaining 39 cents going to those costs.

This margin sits well below the healthcare sector median of 69.8%, placing BAYRY in the 33rd percentile among its peers — indicating that the company is less efficient at generating profit from revenue than two-thirds of the industry. No trend data is available: the year-over-year change is N/A, the quarter-over-quarter change is N/A, and no values are provided for the prior eight quarters, so it is impossible to assess direction. The combination of a below-median gross margin with no observable trend suggests a static but structurally weak cost position, which increases investment risk because the company may lack pricing power or face higher production costs than rivals. This metric directly supports the overall CAUTIOUS verdict: the low gross margin compared to peers is a fundamental concern that justifies a defensive stance on the stock.

Frequently Asked Questions